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insured population who underwent mastectomy for breast cancer
then ﬁlled a ﬁrst prescription for an oral adjuvant hormonal
agent (OAHA, deﬁned as tamoxifen or an aromatase inhibitor)
within one year after surgery, and had continuous eligibility for
pharmacy beneﬁts from six months prior to surgery. Patients
were excluded if they had claims coded for distant metastasis or
chemotherapy agents speciﬁc for advanced cancer. Days covered
by OAHA are deduced from dispensed dates and days supplied.
Time to nonpersistence (deﬁned as 180 days without OAHA
coverage) is estimated using a Kaplan-Meier analysis and the
relation assessed between time to nonpersistence and age and
history of cytotoxic adjuvant chemotherapy or radiation therapy
preceding endocrine therapy. RESULTS: A total fo 3654 women
(age mean 59.8, SD 12.4) were identiﬁed who satisﬁed study
criteria, underwent mastectomy between July1998 and Decem-
ber 2006, and had pharmacy beneﬁts eligibility extending
through 2007 or at least 180 days after deduced exhaustion of
last OAHA supply. A total of 33.2% had claims consistent with
cytotoxic adjuvant chemotherapy and 65% had claims for radia-
tion therapy. Including as right-censored patients still receiving
therapy at study end (n = 1516) and those lost to follow-up
(n = 969), the cumulative nonpersistence rate is estimated as
24% at three years. Nonpersistence rates were higher for the
youngest and oldest patients, and lower for patients with a
preceding history of cytotoxic chemotherapy or radiation
therapy. CONCLUSION: It is important to increase understand-
ing of the determinants of persistence with cancer therapies
administered orally for long time periods.
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OBJECTIVE: The prevalence of prostate cancer increases with
age. Leuprolide acetate is an efﬁcacious therapy in patients with
prostate cancer. Therapy persistence is essential for desirable
clinical outcomes. METHODS: A retrospective analysis was con-
ducted using the Medstat MarketScan database on a commer-
cially and Medicare aged insured population from 2001–2005.
The MarketScan database collects medical claims, pharmacy
claims, cost, and demographics data. Subjects new to leuprolide
acetate (identiﬁed by J-Code of J9217) in 2002 and no codes in
2001 were followed for 3 years. Compliance was calculated
using the medication possession ratio (MPR = total days supply
obtained/days on therapy). Persistence was characterized by the
number of ﬁlls and the days on therapy (start plus estimated
discontinuation date). Subjects were stratiﬁed into age-range
groups, by those >18 and <51 yr, those >81 yr, and 10-year age
ranges in between (51–60, 61–70, 71–80). Survival rate was
calculated using Kaplan–Meier survival curves. RESULTS: A
total of 1541 men with prostate cancer receiving leuprolide
acetate were included in the study. The average MPR for all ages
was 0.70 (Standard Deviation [SD] = 0.15) and did not change
signiﬁcantly by age. Average months persistence was 15.9
months (SD = 11.8, N = 1541) and generally increased with age
from 10.6 months (SD = 12.4, N = 59) for those 18–50 years;
14.8 months (SD = 13.5, N = 188) for those 51–60 years; 12.5
months (SD = 11.2, n = 302) for those 61–70 years; 16.7 months
(SD = 11.4, N = 718) for those 71–80 years; and 19.8 months
(SD = 10.4, N = 274) for those over 80 years. More than one-
third of patients discontinued by six months of therapy.
CONCLUSION: Leuprolide acetate therapy persistence in-
creased with age. Persistency improvement efforts in younger
patients and during the ﬁrst six months of therapy may result in
better outcomes.
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OBJECTIVE: To examine differences in medication adherence to
adjuvant hormonal therapy between white and black patients
with breast cancer using different statistical techniques. The data
source: Linked North Carolina Medicaid claims-Tumor Registry
data (years 1999–2005). METHODS: The study design was a
retrospective cohort study of Medicaid enrollees with breast
cancer newly starting adjuvant hormonal therapy (tamoxifen or
aromatase inhibitor) between years January 2000 to December
2004. Medication adherence [measured as Medication Posses-
sion Ratio (MPR)] was assessed using patients’ prescription reﬁll
records. The Medicaid claims and CCR data were merged using
a probabilistic match algorithm. From the linked data, informa-
tion on patients with ICD-9 codes for primary breast cancer was
extracted. RESULTS: Black patients had a 7% and 9% lower
adherence rate as compared to white patients in the propensity
score and regression method respectively. Stratiﬁcation based on
80% cut-off point for the MPR showed that black patients were
21% less likely to be in the high adherence group. CONCLU-
SION: Results from the propensity score and regression analysis
may agree so closely in this study because there was good overlap
in the distribution of background characteristics for the white
and black women with primary breast cancer enrolled in
Medicaid.
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OBJECTIVE: To determine predictors of quality of life (QoL)
in community-dwelling prostate cancer (PC) survivors.
METHODS: We derived a population-based sample of PC
patients diagnosed in 1993–4, 1997–8 and 2001–2, residing in
3 geographically diverse areas of Ontario, from the Ontario
Cancer Registry (n = 2749, survivors = 1961). Consenting survi-
vors (n = 851) were mailed questionnaires, including the Health
Utilities Index (HUI 2/3), Patient-Oriented Prostate Utility
Scale [PORPUS-P (psychometric) and PORPUS-Ui (utility)],
Functional Assessment of Cancer Therapy-Prostate (FACT-P),
Prostate Cancer Index (PCI), and a consent form for chart review.
We constructed univariate and multivariate regression models to
determine the effects of patient-, disease-, system-, and symptom-
related variables on QoL. RESULTS: A total of 670 patients
returned completed questionnaires and 620 charts were reviewed
(others lost, destroyed; 597 entered for these analyses). Mean
(SD) PORPUS-P score was 71.78 (14.00), mean PORPUS-Ui
was 0.86 (0.11), mean HUI3 was 0.78 (0.24), and mean FACT-P
was 127.26 (18.40). In univariate analyses with patient-related
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variables (age, marital status, education, employment, income,
comorbidity), older age, widowhood, lower education, retire-
ment, and comorbidity (Charlson > 2), were associated with
lower QoL (all p < 0.05). In multivariate analyses, all patient-
related variables explained 18–21% of the variance in scores.
With the addition of disease-related variables (treatment with
radical prostatectomy, radiation, or hormones; metastases,
Gleason score at diagnosis), the model explained 21–25% of the
variance. Patients currently on hormone treatment had lower
PORPUS-Ui and HUI3 scores than patients treated with hor-
mones in the past or never (p < 0.05). System-related variables
(year and county of diagnosis) contributed little to the explained
variance (1–3%). Symptom-related variables (PCI urinary,
sexual, bowel function) were the strongest predictors of QOL
(explaining 47–70% of the variance). CONCLUSION: Symp-
toms related to PC and its treatment have large effects on the
QoL of PC survivors. Although many variables are associated
with QoL, only prostate symptoms and comorbidity have inde-
pendent effects.
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OBJECTIVE: A multicenter phase III trial showed patients with
stage III or IV follicular lymphoma who achieved a partial or
complete remission after ﬁrst-line treatment receiving 90Y-
ibritumomab tiuxetan had signiﬁcantly longer PFS time as com-
pared to similar patients receiving no treatment. The objective of
this study was to determine the impact of 90Y-ibritumomab
tiuxetan on health-related quality of life. METHODS: Health-
related quality of life was assessed using EORTC QLQ-C30
version 2 and EuroQoL-5D (EQ-5D) questionnaires. These ques-
tionnaires were administered at screening, week 14 and every 6
months thereafter and ﬁnally at end of follow-up. Descriptive
statistics were used to compare scores across treatment groups.
The change in scores from baseline was also assessed by gender,
age and ﬁrst-line treatment. Mixed effects model was used to
assess the factors that were associated with ﬁnal scores of Visual
Analogue Scale (VAS) of EQ-5D.RESULTS:Nonotable treatment
differences were observed in the scores of EORTC QLQ-C30 (all
domains) scores across timepoints or changes from baseline. This
result was true for all sub-groups. The mean scores for EQ-5D at
screening and ﬁnal visit were 0.83 and 0.84 for 90Y-ibritumomab
tiuxetan and 0.84 and 0.83 for control arm. The mean VAS scores
at screening and ﬁnal visit were 77.52 and 77.64 for 90Y-
ibritumomab tiuxetan and 76.57 and 78.51 for control arm. An
analysis of factors associated with ﬁnal VAS scores showed that
baseline VAS scores affected ﬁnal VAS scores (p < 0.0001). CON-
CLUSION: There appears to be no difference in quality of life for
patients on 90Y-ibritumomab tiuxetan as compared to those in
control arm as measured by EORTC QLQ C-30 and EQ-5D
questionnaires. 90Y-ibritumomab tiuxetan prolongs PFS without
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OBJECTIVE: To quantify the impact of disease and its treatment
on patient-reported well-being, it is important to consider the
patient’s economic circumstances. This study explored the rela-
tionship between annual household income and health-related
psychological well-being among insured, long-term (>ﬁve years)
colorectal cancer (CRC) survivors with and without permanent
intestinal stomas. METHODS: This is a secondary analysis of
data collected as part of an NCI-funded study of health-related
quality of life (HRQOL) among CRC survivors, in which 681
respondents (52% response rate) completed a survey instrument
that included the modiﬁed City of Hope Quality of Life (mCOH-
QOL)–Ostomy questionnaire, SF-36 v2, and socio-demographic
items. Of these, 588 subjects provided income data and were
included in this analysis. The mCOH-QOL–Ostomy is based on
a four-dimension model of HRQOL (physical, psychological,
social, and spiritual well-being). For this analysis, the dependent
variable was the psychological well-being (PWB) score. Hierar-
chical linear regression was used to explore the unique contribu-
tion of income to the total variance of PWB over and above the
model that included the following independent variables: self-
reported physical health (SF-36v2 PCS), co-morbidity (Charlson-
Deyo), age, sex, race/ethnicity, education, partnered status, and
presence of an ostomy. RESULTS: After accounting for the pro-
portion of variance in PWB explained by the other independent
variables, the additional variance explained by income was sig-
niﬁcant (R2 increased from 0.228 to 0.250; p = 0.006). When
compared to those in the highest household income category
(>$100,000), subjects in the lowest income category (<$5000)
had a clinically meaningful 0.82 point lower PWB score on the
11-point scale. Signiﬁcant positive predictors of PWB were PCS
score, age, and absence of an ostomy. CONCLUSION: Although
the study design does not allow causal inference, these results
demonstrate a signiﬁcant relationship between income and PWB
that merits further consideration when attempting to interpret
patient-reported outcomes, particularly HRQOL.
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OBJECTIVE: To provide qualitative data on the men’s experi-
ence, impact and relative importance of hot ﬂushes as a result of
prostate cancer therapies, with an emphasis on gonadotropin-
releasing hormone (GnRH) agonists. METHODS: A qualitative
study applying a non-probabilistic purposive sampling strategy.
Participants were over 50 years old with histologically conﬁrmed
adenocarcinoma of the prostate, had recently initiated (6
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